Company: PRTA
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001559053-25-000031
Chunk: 20

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-08-04
Form: 10-Q
Item: Part I, Item 1
Chunk 20
---
 conclude it is probable that a significant revenue reversal will not occur in future periods.

Revenue Recognition

Noe three and six months ended June 30, 2025 and 2024, respectively. The Company had noJune 30, 2025, and December 31, 2024, respectively.

8. Shareholders' Equity

Ordinary Shares

As of June 30, 2025, the Company had 100,000,000 0.01 53,826,982 one 17,193,490

Euro Deferred Shares

As of June 30, 2025, the Company had 10,000 22 No pari passu with the ordinary shares and are treated as a single class in all respects.

At-the-Market Offerings

In December 2021, the Company entered into an Equity Distribution Agreement (the “ December 2021 Distribution Agreement”), pursuant to which the Company could issue and sell, from time to time, the Company's ordinary shares. In connection with entering into the December 2021 Distribution Agreement, on December 23, 2021, the Company filed with the SEC a prospectus supplement relating to the offer, issuance and sale of up to $ 250.0

TheDecember2021 Prospectus was no longer effective as ofMarch 23, 2024. A s ofMarch 23, 2024, the Company had sold and issued953,589 ordinary shares pursuant to the December 2021 Distribution Agreement under theDecember 2021 Prospectus for t otal gross proceeds of approximately$ 56.3 before deducting underwriting discounts, commissions, and other offering expenses paid by the Company of$ 1.8

In February 2024, the Company amended the Equity Distribution Agreement that it entered into in December 2021 (the “ Amended Distribution Agreement”), pursuant to which the Company may issue and sell, from time to time, the Company's ordinary shares. In connection with amending the Amended Distribution Agreement, on February 22, 2024, the Company filed with the SEC a prospectus relating to the offer, issuance, and sale of up to $ 250.0 For the three and six months ended June 30, 2025 and 2024, t he Company sold and issued no ordinary shares pursuant to the Amended Distribution Agreement under the February 2024 Prospectus.

The issuance and sale of the Company’s ordinary shares pursuant to the December 2021 Distribution Agreement and the